Clinical Trials in Thalassemia Cell and Gene Therapy Application supports investigators conducting cell and gene therapy trials and related preclinical work to advance a cure for thalassemia.
Applications for 2027–2028 are now open; the December 15, 2025 LOI and February 9, 2026 application deadlines were removed without replacements. Indirect costs increased from 8% to up to 10%, in vivo gene therapy and toxicity-reduction proposals are now encouraged, and other application details also changed.
Ongoing Clinical Research in Thalassemia Application supports investigators conducting patient-centered clinical studies to address health, quality-of-life, and disease-burden issues in thalassemia.
Research Fellowship Grant Application supports postdoctoral and junior faculty investigators studying thalassemia and its complications to improve understanding or treatment and benefit patients.
Career Development Awards from ASGCT support early-career scientists and postdoctoral fellows with transformative gene and cell therapy pilot studies to build independent research careers.
Academic Clinical Trials Program (ACT) supports academic investigators conducting blood cancer trials to test new treatments, expand existing therapy uses, and improve care for unmet medical needs.
NTSAD-ASGCT Translational Research Fellowship supports fellows and scientists pursuing translational research to advance genetic medicines toward clinical use for four rare neurogenetic diseases.